组学联用技术在类风湿关节炎患者早期诊断和治疗中的应用价值

注册号:

Registration number:

ChiCTR2400081579 

最近更新日期:

Date of Last Refreshed on:

2024-06-24 09:18:41 

注册时间:

Date of Registration:

2024-03-05 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

组学联用技术在类风湿关节炎患者早期诊断和治疗中的应用价值

Public title:

The value of combined omics technique in the early diagnosis and treatment of rheumatoid arthritis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

组学联用技术在类风湿关节炎患者早期诊断和治疗中的应用价值

Scientific title:

The value of combined omics technique in the early diagnosis and treatment of rheumatoid arthritis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

卢伟锋 

研究负责人:

解丹丹 

Applicant:

luweifeng 

Study leader:

xiedandan 

申请注册联系人电话:

Applicant telephone:

+86 13976610741

研究负责人电话:

Study leader's
telephone:

+86 13707572197

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

345101204@qq.com

研究负责人电子邮件:

Study leader's E-mail:

254862958@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

海南省海口市龙华区龙华路31号海南医学院第一附属医院

研究负责人通讯地址:

海南省海口市龙华区31号

Applicant address:

No. 31 Hainan Medical College Road, Longhua District, Haikou City, Hainan Province first affiliated

Study leader's address:

31 Longhua District, Haikou City, Hainan Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

海南医学院第一附属医院

Applicant's institution:

First Affiliated Hospital of the Hainan Medical College

研究负责人所在单位:

海南医学院第一附属医院

Affiliation of the Leader:

Hainan Medical College First Affiliated Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024-KYL-056

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

海南医学院第一附属医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the First Affiliated Hospital of Hainan Medical College

伦理委员会批准日期:

Date of approved by ethic committee:

2024-02-07 00:00:00

伦理委员会联系人:

林萍

Contact Name of the ethic committee:

Lin Ping

伦理委员会联系地址:

海南省海口市龙华区31号

Contact Address of the ethic committee:

31 Longhua District, Haikou City, Hainan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 898 66735891

伦理委员会联系人邮箱:

Contact email of the ethic committee:

hyfylunli@163.com

研究实施负责(组长)单位:

海南医学院第一附属医院

Primary sponsor:

Hainan Medical College First Affiliated Hospital

研究实施负责(组长)单位地址:

海南省海口市龙华区31号

Primary sponsor's address:

31 Longhua District, Haikou City, Hainan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

海南

市(区县):

Country:

China

Province:

Hainan

City:

单位(医院):

海南医学院第一附属医院

具体地址:

海南省海口市龙华区31号

Institution
hospital:

Hainan Medical College First Affiliated Hospital

Address:

31 Longhua District, Haikou City, Hainan Province

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

self-funded

研究疾病:

类风湿关节炎  

Target disease:

Rheumatoid arthritis

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

采用蛋白组学联合代谢组学技术对类风湿关节炎患者进行有效生物标志物和治疗靶点筛选  

Objectives of Study:

Proteomics combined with metabonomics was used to screen effective biomarkers and therapeutic targets in patients with rheumatoid arthritis

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.合并有严重的心血管、肝脏、肺部等疾病者;;
2.合并有出血倾向疾病;
3.合并有系统性红斑狼疮、系统性硬化症、强直性脊柱炎、骨关节炎等其他风湿性疾病;
4.伴严重精神心理疾病;
5.妊娠期或哺乳期妇女;
6.因感染、肿瘤等其他疾病引起的关节肿痛;
7.严重凝血功能障碍;

Exclusion criteria:

1.patients with severe cardiovascular, liver and lung diseases;
2.Combined with bleeding tendency disease;
3.There are systemic lupus erythematosus, systemic sclerosis, ankylosing spondylitis, osteoarthritis and other rheumatic diseases;
4.With severe mental illness;
5.A woman who is pregnant or nursing;
6.Joint swelling and pain caused by infection, tumor and other diseases;
7.Serious Coagulopathy;

研究实施时间:

Study execute time:

From 2024-03-01 00:00:00 To 2026-01-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-03-11 00:00:00 To 2026-01-31 00:00:00

干预措施:

Interventions:

组别:

类风湿关节炎病例组

样本量:

100

Group:

Rheumatoid arthritis case group

Sample size:

干预措施:

类风湿关节炎

干预措施代码:

Intervention:

Rheumatoid arthritis

Intervention code:

组别:

健康对照组

样本量:

100

Group:

Healthy control group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

组别:

类风湿关节炎关节置换手术

样本量:

50

Group:

Arthroplasty for rheumatoid arthritis

Sample size:

干预措施:

关节置换手术

干预措施代码:

Intervention:

Joint replacement surgery

Intervention code:

组别:

退行性病变关节置换

样本量:

50

Group:

Joint replacement of degenerative disease

Sample size:

干预措施:

关节置换手术

干预措施代码:

Intervention:

Joint replacement surgery

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

海南 

市(区县):

 

Country:

China

Province:

Hainan

City:

单位(医院):

海南医学院第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

Hainan Medical College First Affiliated Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

海南 

市(区县):

 

Country:

China

Province:

Hainan

City:

单位(医院):

海南医学院第二附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Affiliated Hospital of Hainan Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

蛋白组学联合代谢组学检测

指标类型:

主要指标

Outcome:

Proteomics combined with metabolomics assay

Type:

Primary indicator

测量时间点:

样本收集后集中测量

测量方法:

蛋白组学联合代谢组学技术

Measure time point of outcome:

The samples were collected and measured centrally

Measure method:

Combined proteomics and metabolomics techniques

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

关节组织

组织:

Sample Name:

Joint tissue

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Do not share

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2024-03-05 15:20:28